Frontlight ResearchEarly access
TerminatedPhase 1
Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or Obesity
Key facts
- Who runs it
- Pfizer
- Where
- Anaheim, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Phase 1
- People taking part
- 21 people enrolled
- Started
- 13 Mar 2025
- Ended
- 20 May 2025
- Type of study
- Interventional
- Treatments tested
- PF-07976016
- PF-06882961
- Record updated
- 7 August 2025
- Why it stopped
- The sponsor has made the decision to discontinue development of danuglipron (PF-06882961). As such, this study was discontinued prior to PF-06882961 administration.
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Male and non-pregnant, non-breastfeeding female, 18 to 65 years of age
- BMI 25 to 40 kg/m2 and a total body weight > 50 kg (110 lb)
- Willing and able to comply with all study procedures including staying a research unit for up to 95 days
Who cannot take part
- Use of any prohibited prior or concomitant medication(s)
- A positive urine drug test
- History of alcohol abuse or repeated binge drinking and/or any other illicit drug use or dependence
- Any medical or psychiatric condition or laboratory abnormality, or recent serious illness or hospitalization, that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study including diagnosis of type 2 diabetes mellitus, type 1 or secondary forms of diabetes
- Presence of specified abnormalities on diagnostic assessments including clinical laboratory tests
- Use of tobacco/nicotine containing products in excess of the equivalent of 5 cigarettes/day or 2 chews of tobacco/day
Where in United States
- Anaheim Clinical Trials, LLCAnaheim, United States
About the trial
What the trial wants to find out
The purpose of this study is to see how two study medicines, PF-07976016 and danuglipron, taken together affect the level of each other in the blood of participants who have overweight or obesity.
Read full original descriptionShow less
The total number of weeks of the study is up to approximately 22 weeks (5.5 months).
The group in the trial
- Period 1Treatment being tested
Participants will receive doses of PF-07976016 with and without PF-06882961
Treatment: PF-07976016 and PF-06882961
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO EVALUATE THE PHARMACOKINETIC INTERACTIONS BETWEEN PF-07976016 AND PF-06882961 IN OTHERWISE HEALTHY ADULT PARTICIPANTS WITH OVERWEIGHT OR OBESITY
- Record updated
- 7 August 2025